Company news

Aytu BioPharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aytu Reports Q2 Revenue of $3.2M, Up 77% Year-over-Year and 121% Sequentially

February 12, 2020

Aytu BioScience to Report Fiscal Q2 FY 2020 Results and Business Update

February 5, 2020

Aytu BioScience Announces Acceptance of Results of Two Natesto Clinical Studies for Presentation at American Urological Association Annual Scientific Program

February 4, 2020

Aytu BioScience Announces Acceptance of Natesto Spermatogenesis Study Results for Presentation at ENDO 2020

January 27, 2020

Aytu BioScience and Innovus Pharmaceuticals Announce Effectiveness of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience

January 26, 2020

Aytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience

December 23, 2019

Aytu BioScience Announces Launch of Natesto(R) U.S. Co-Promotion with Acerus Pharmaceuticals

December 1, 2019

Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading Pharmacy Benefit Manager’s National Formulary

November 18, 2019

Aytu Reports First Quarter 2020 Financial Results

November 13, 2019

Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations

November 10, 2019

Aytu BioScience to Report Fiscal Q1 FY 2020 Results and Business Update

November 6, 2019

Aytu BioScience Announces Closing of $12.4M Prescription Product Portfolio Purchase

November 3, 2019

Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading National Pharmacy Benefit Manager's Formulary

October 20, 2019

Aytu BioScience Announces Positive Clinical Results from Natesto(R) Spermatogenesis Study

October 16, 2019

Aytu BioScience to Announce Results from Natesto(R) Spermatogenesis Study on Thursday, October 17

October 15, 2019

Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio

October 13, 2019

Aytu BioScience and Validus Pharmaceuticals Announce ZolpiMist Co-Promotion Agreement and Launch Into the $163 Million Psychiatry Market

October 1, 2019

Aytu BioScience Reports 100% Revenue Growth to $7.3 million in FY 2019

September 25, 2019

Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Manager’s Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives

September 23, 2019

Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals

September 11, 2019

Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in South Africa

September 9, 2019

Aytu BioScience Announces Tuzistra XR Co-Promotion Agreement with Poly Pharmaceuticals

September 3, 2019

← Newer news releases

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.